Abstract
Background: Bone giant cell tumor (BGCT) is a locally aggressive primary bone tumor. While denosumab is the current standard systemic treatment, its use is limited by high local recurrence rates after discontinuation and potential long-term side effects. This study utilizes bioinformatics to identify alternative genetic targets and potential drugs for BGCT treatment.
Methods: A multi-stage pipeline was employed, starting with text mining via pubmed2ensembl to identify genes shared between BGCT and fracture healing. These genes underwent functional enrichment analysis (DAVID) and protein-protein interaction (PPI) network modeling (STRING/Cytoscape). Finally, hub genes were queried against the Drug Gene Interaction Database (DGIdb) to identify therapeutic candidates.
Results: The study identified 123 genes common to BGCT and fracture healing. Further analysis narrowed this to seven central hub genes: ANGPT2, COL1A1, COL1A2, CTSK, FGFR1, NTRK2, and PDGFB. Interaction analysis identified 17 potential drugs, including 15 antineoplastic agents, one anti-osteoporosis drug, and one anti-influenza drug.
Conclusion: The identified hub genes and 17 candidate drugs—six of which are already FDA-approved for other indications—represent promising avenues for drug repositioning to improve BGCT outcomes.
Introduction
Bone Giant Cell Tumor (BGCT) is a locally aggressive primary bone tumor that typically affects the epiphyses of long bones in young adults. Although rarely metastatic, BGCT is highly destructive to local bone tissue. The current pharmacological "gold standard" is denosumab, a monoclonal antibody that inhibits bone resorption. However, denosumab is often a temporary solution; local recurrence rates spike once treatment stops, and long-term use is associated with complications such as osteonecrosis of the jaw. There is a critical clinical need for alternative therapeutic targets that can manage the tumor more effectively or provide options when denosumab is unsuitable.
Methodology
To address this, researchers developed a bioinformatics pipeline to bridge the gap between existing literature and clinical application:
- Text Mining: Using the
pubmed2ensemblservice, the team identified genes associated with "Bone Giant-cell tumor" and "Fracture healing." The rationale is that both processes involve intense bone remodeling and shared signaling pathways. - Functional Enrichment: The DAVID database was used for Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analyses to understand the biological roles of overlapping genes.
- Network Analysis: Protein-Protein Interaction (PPI) networks were constructed using STRING and Cytoscape. The MCODE plugin was used to extract highly connected "hub" genes.
- Drug-Gene Interaction: Hub genes were queried against the Drug Gene Interaction Database (DGIdb) to find existing drugs that target these proteins.
Key Insights and Results
The Fracture Healing Proxy
A central premise of this study is that fracture healing serves as a biological template for BGCT. Both involve massive osteoclastic activity and bone repair attempts. By identifying 123 genes common to both processes, the researchers highlighted the dysregulated pathways driving tumor progression.
Pathway and Hub Gene Identification
KEGG analysis identified the PI3K-Akt and MAPK signaling pathways as strongly correlated with BGCT. From the initial pool of 123 genes, seven were identified as central "hubs" of the molecular network: ANGPT2, COL1A1, COL1A2, CTSK, FGFR1, NTRK2, and PDGFB. Experimental validation using qRT-PCR on patient tissues confirmed the significant upregulation of five of these genes (NTRK2, FGFR1, PDGFB, COL1A1, and COL1A2) in tumor samples compared to healthy controls.
Drug Repositioning Potential
The analysis identified 17 drugs targeting these hub genes. Notably, six of these—including Sunitinib and Nintedanib—are already FDA-approved for other conditions. This suggests a significant opportunity for drug repositioning, which could shorten the timeline for clinical trials in BGCT.
Conclusion and Future Directions
This study provides a molecular roadmap for alternative BGCT treatments. By targeting hub genes involved in both bone remodeling and tumor growth, clinicians may find alternatives to denosumab. However, the study is limited by a small validation cohort (n=12) and a lack of functional in vitro or in vivo assays. Future research should focus on testing the top-tier FDA-approved candidates in clinical settings, particularly for patients who are non-responsive to current therapies.
Summary updated